91 related articles for article (PubMed ID: 20865381)
1. Role of the gut Peptide glucose-induced insulinomimetic Peptide in energy balance.
Pfeiffer AF; Rudovich N; Weickert MO; Isken F
Results Probl Cell Differ; 2010; 52():183-8. PubMed ID: 20865381
[TBL] [Abstract][Full Text] [Related]
2. Glucose-dependent Insulinotropic Polypeptide (GIP): From prohormone to actions in endocrine pancreas and adipose tissue.
Ugleholdt R
Dan Med Bull; 2011 Dec; 58(12):B4368. PubMed ID: 22142579
[TBL] [Abstract][Full Text] [Related]
3. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action.
Zhou H; Yamada Y; Tsukiyama K; Miyawaki K; Hosokawa M; Nagashima K; Toyoda K; Naitoh R; Mizunoya W; Fushiki T; Kadowaki T; Seino Y
Biochem Biophys Res Commun; 2005 Sep; 335(3):937-42. PubMed ID: 16105663
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice.
Irwin N; Montgomery IA; Flatt PR
Br J Nutr; 2012 Jul; 108(1):46-56. PubMed ID: 22260799
[TBL] [Abstract][Full Text] [Related]
5. Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes.
Yamada C; Yamada Y; Tsukiyama K; Yamada K; Yamane S; Harada N; Miyawaki K; Seino Y; Inagaki N
Biochem Biophys Res Commun; 2007 Dec; 364(1):175-80. PubMed ID: 17937928
[TBL] [Abstract][Full Text] [Related]
6. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
7. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
8. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
Meier JJ; Nauck MA
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):587-606. PubMed ID: 15533777
[TBL] [Abstract][Full Text] [Related]
9. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
10. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.
Irwin N; McClean PL; Patterson S; Hunter K; Flatt PR
Biol Chem; 2009 Jan; 390(1):75-80. PubMed ID: 18937625
[TBL] [Abstract][Full Text] [Related]
11. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
12. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
[TBL] [Abstract][Full Text] [Related]
13. RS4-type resistant starch prevents high-fat diet-induced obesity via increased hepatic fatty acid oxidation and decreased postprandial GIP in C57BL/6J mice.
Shimotoyodome A; Suzuki J; Fukuoka D; Tokimitsu I; Hase T
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E652-62. PubMed ID: 20009028
[TBL] [Abstract][Full Text] [Related]
14. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.
Hansotia T; Maida A; Flock G; Yamada Y; Tsukiyama K; Seino Y; Drucker DJ
J Clin Invest; 2007 Jan; 117(1):143-52. PubMed ID: 17187081
[TBL] [Abstract][Full Text] [Related]
15. PYY transgenic mice are protected against diet-induced and genetic obesity.
Boey D; Lin S; Enriquez RF; Lee NJ; Slack K; Couzens M; Baldock PA; Herzog H; Sainsbury A
Neuropeptides; 2008 Feb; 42(1):19-30. PubMed ID: 18164057
[TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.
Paschetta E; Hvalryg M; Musso G
Obes Rev; 2011 Oct; 12(10):813-28. PubMed ID: 21815989
[TBL] [Abstract][Full Text] [Related]
17. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).
McIntosh CH; Widenmaier S; Kim SJ
Vitam Horm; 2009; 80():409-71. PubMed ID: 19251046
[TBL] [Abstract][Full Text] [Related]
18. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
[TBL] [Abstract][Full Text] [Related]
19. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
[TBL] [Abstract][Full Text] [Related]
20. Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant.
Yammine L; Picatoste B; Abdullah N; Leahey RA; Johnson EF; Gómez-Banoy N; Rosselot C; Wen J; Hossain T; Goncalves MD; Lo JC; Garcia-Ocaña A; McGraw TE
Mol Metab; 2023 Dec; 78():101831. PubMed ID: 37925022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
